A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

Phase 1/2 Study of PF-06463922 (an ALK/ROS1 Tyrosine Kinase Inhibitor) in Patients With Advanced Non-Small Cell Lung Cancer Harboring Specific Molecular Alterations

Category & Conditions:
Cancer
Medicine:
Lorbrena (lorlatinib)
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
B7461001
Open Plain Language Summary Result:Click here